TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making

Megan Coylewright; John K Forrest; James M McCabe; Tamim M Nazif

doi:10.1016/j.jacc.2019.12.057

TAVR in Low-Risk Patients: FDA Approval, the New NCD, and Shared Decision-Making

J Am Coll Cardiol. 2020 Mar 17;75(10):1208-1211. doi: 10.1016/j.jacc.2019.12.057.

Authors

Megan Coylewright¹, John K Forrest², James M McCabe³, Tamim M Nazif⁴

Affiliations

¹ Section of Cardiovascular Medicine, Heart and Vascular Center, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire. Electronic address: megan.coylewright@hitchcock.org.
² Cardiovascular Medicine, Yale University School of Medicine, New Haven, Connecticut.
³ Division of Cardiology, University of Washington Medical Center, Seattle, Washington.
⁴ Structural Heart and Valve Center, Columbia University Medical Center, New York, New York.

PMID: 32164894
DOI: 10.1016/j.jacc.2019.12.057

No abstract available

Keywords: Food and Drug Administration; heart team; national coverage determination; shared decision-making; transcatheter aortic valve replacement.

Publication types

Review

MeSH terms

Aortic Valve Stenosis / epidemiology
Aortic Valve Stenosis / surgery*
Clinical Decision-Making / methods*
Decision Making, Shared*
Device Approval*
Humans
Insurance Coverage* / trends
Risk Factors
Transcatheter Aortic Valve Replacement / methods*
Transcatheter Aortic Valve Replacement / trends